The effect of intervention by an antimicrobial stewardship team on anaerobic bacteremia.
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ therapeutic use
Antimicrobial Stewardship
Bacteremia
/ microbiology
Bacteria, Anaerobic
/ drug effects
Carbapenems
/ therapeutic use
Female
Hospitals, University
Humans
Male
Middle Aged
Piperacillin, Tazobactam Drug Combination
/ therapeutic use
Prognosis
Treatment Outcome
Anaerobic bacteremia
Antimicrobial stewardship
Bacteroides species
Carbapenem
de-escalation
Journal
Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
05
03
2020
revised:
13
05
2020
accepted:
14
05
2020
pubmed:
25
5
2020
medline:
9
6
2021
entrez:
25
5
2020
Statut:
ppublish
Résumé
The effect of antimicrobial stewardship (AS) on anaerobic bacteremia is uncertain. This study aimed to assess the effect of interventions by the AS team (AST) on clinical and microbiological outcomes and antimicrobial use. An AS program was introduced at Osaka City University Hospital in January 2014; an interdisciplinary AST was established. We enrolled patients with anaerobic bacteremia between January 2009 and December 2018. Patients were classified into the pre-intervention group (from January 2009 to December 2013) and the post-intervention group (from January 2014 to December 2018). A significant decrease in definitive carbapenem use (P = 0.0242) and an increase in empiric tazobactam/piperacillin use (P = 0.0262) were observed in the post-intervention group. The de-escalation rate increased significantly from 9.38% to 32.7% (P = 0.0316) in the post-intervention group. The susceptibility of Bacteroides species and 30-day mortality did not worsen in the post-intervention group. These results showed that interventions by an AST can reduce carbapenem use and increase the de-escalation rate without worsening patient outcomes.
Identifiants
pubmed: 32446953
pii: S1075-9964(20)30070-6
doi: 10.1016/j.anaerobe.2020.102214
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Piperacillin, Tazobactam Drug Combination
157044-21-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102214Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.